CAMBRIDGE, MA — November 5, 2026 — NeuroBionics, a neurotechnology company developing minimally invasive implantable devices for neuromodulation therapy, today announced it has received a £4.6M grant from the UK’s Advanced Research + Invention Agency (ARIA). The award is part of ARIA’s £50M Massively Scalable Neurotechnologies programme, which is funding radically new ways to deliver responsive neurotechnologies to the brain without brain surgery.
The grant will accelerate development of NeuroBionics’ endovascular neuromodulation platform: a hair-thin device deployed through blood vessels to deliver therapy to targets in the brain and across the body. Building on more than a decade of innovation at MIT, NeuroBionics aims to eliminate the open surgical procedures required to implant today’s neuromodulation devices and expand access to these therapies for millions of patients with neurological disorders.